- Home
- NIVF vs VTAK Comparison
NIVF vs VTAK Comparison
Compare NIVF & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- VTAK
- Stock Information
- Founded
- NIVF 2011
- VTAK 2002
- Country
- NIVF Hong Kong
- VTAK United States
- Employees
- NIVF N/A
- VTAK N/A
- Industry
- NIVF
- VTAK Medical/Dental Instruments
- Sector
- NIVF
- VTAK Health Care
- Exchange
- NIVF NYSE
- VTAK Nasdaq
- Market Cap
- NIVF 3.9M
- VTAK 3.1M
- IPO Year
- NIVF N/A
- VTAK 2018
- Fundamental
- Price
- NIVF $2.11
- VTAK $0.35
- Analyst Decision
- NIVF
- VTAK
- Analyst Count
- NIVF 0
- VTAK 0
- Target Price
- NIVF N/A
- VTAK N/A
- AVG Volume (30 Days)
- NIVF 2.6M
- VTAK 149.8K
- Earning Date
- NIVF 02-16-2025
- VTAK 03-31-2025
- Dividend Yield
- NIVF N/A
- VTAK N/A
- EPS Growth
- NIVF N/A
- VTAK N/A
- EPS
- NIVF N/A
- VTAK N/A
- Revenue
- NIVF $5,679,218.00
- VTAK $399,000.00
- Revenue This Year
- NIVF N/A
- VTAK $38.46
- Revenue Next Year
- NIVF N/A
- VTAK $533.33
- P/E Ratio
- NIVF N/A
- VTAK N/A
- Revenue Growth
- NIVF N/A
- VTAK 27.07
- 52 Week Low
- NIVF $0.11
- VTAK $0.31
- 52 Week High
- NIVF $17.24
- VTAK $4.10
- Technical
- Relative Strength Index (RSI)
- NIVF 76.40
- VTAK 34.81
- Support Level
- NIVF $1.85
- VTAK $0.33
- Resistance Level
- NIVF $2.89
- VTAK $0.43
- Average True Range (ATR)
- NIVF 0.30
- VTAK 0.03
- MACD
- NIVF 0.18
- VTAK -0.00
- Stochastic Oscillator
- NIVF 72.03
- VTAK 17.00
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System) which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.